RCE ASX · Health Care

Recce Pharmaceuticals Ltd

Announcements, last 12 months: 63
Price sensitive, last 12 months: 25

Latest announcements

Released	Headline	Actions
22 Oct 2026, 9:45 AM	License and Commercialisation Agreement in AUS/NZ for R327G Price sensitive	AI summary
20 Oct 2026, 11:19 AM	Independent Review of Indonesian Phase 3 R327G Trial Data Price sensitive	AI summary
16 Oct 2026, 6:56 PM	Notification regarding unquoted securities - RCE
16 Oct 2026, 3:02 PM	Amendments to Debt Facility with Avenue Capital Group Price sensitive	AI summary
7 Oct 2026, 8:22 AM	Notice of Annual General Meeting/Proxy Form
1 Oct 2026, 4:36 PM	Notification of cessation of securities - RCE
29 Sep 2026, 4:47 PM	Resolutions under section 249N of the Corporations Act
18 Sep 2026, 4:10 PM	2026 Annual General Meeting
2 Sep 2026, 1:12 PM	Results of General Meeting
2 Sep 2026, 10:01 AM	General Meeting Presentation

Sign in to see all RCE announcements.

Guidance history

21 Jul 2026	Recce expects to achieve upcoming Phase 3 clinical trial milestones
1 Jul 2026	Recce Pharmaceuticals Ltd expects a pro-forma cash position of AUD $33.1M
26 Jun 2026	Recce Pharmaceuticals expects to have approximately A$29.5 million in liquidity post the offer.

Sign in to see the full guidance history.

Most followed in Health Care

PME Pro Medicus Ltd
AHC Austco Healthcare Ltd
CSL CSL Ltd
RMD Resmed Inc
TLX TELIX Pharmaceuticals Ltd
CGS Cogstate Ltd
ALC Alcidion Group Ltd
CSX Cleanspace Holdings Ltd

Follow RCE to get its announcements emailed to you, with AI summaries, the full announcement and guidance history, and its most significant announcements.